Iturelix

Drug Profile

Iturelix

Alternative Names: Antide™; Nal-Lys-GnRH; ORF 23541

Latest Information Update: 25 Jan 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ortho-McNeil
  • Developer Bayer Schering Pharma; Ortho-McNeil
  • Class Antineoplastics; Contraceptives
  • Mechanism of Action Gonadotropin releasing hormone inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Benign prostatic hyperplasia; Cancer; Endometriosis; Female infertility; Prostate cancer; Uterine leiomyoma

Most Recent Events

  • 01 Nov 2004 Discontinued - Phase-II for Female infertility in Europe (unspecified route)
  • 01 Nov 2004 Discontinued - Preclinical for Benign prostatic hyperplasia in Switzerland (unspecified route)
  • 01 Nov 2004 Discontinued - Preclinical for Endometriosis in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top